Head-to-head · free
Linkage Global Inc. Class A Ordinary Shares vs Exascale Labs
UZX vs XLAB — return on capital, cash generation, margins and balance sheet side by side.
UZX
2 / 3
measures where UZX leads
XLAB
1 / 3
measures where XLAB leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | UZX | XLAB · FY2026 |
|---|---|---|
| Revenue | — | $14.8M |
| Net income | — | (12.2M) |
| Revenue growth (yearly, multi-year) | — | — |
| Free cash flow | — | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -63.1% | — |
| Gross margin | 72.6% | 15.8% |
| Operating margin | -90.1% | -43.4% |
| Net debt / EBITDA | -0.48x | 1.39x |
Figures are as reported by each company; latest fiscal year shown.
Where Exascale Labs's cash went (FY2026)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free